利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

43 条记录 (耗时 0.017 秒)

    Ultra-long acting insulin-Fc fusion proteins and methods of use
    1.
    发明授权
    Ultra-long acting insulin-Fc fusion proteins and methods of use 有权

    公开(公告)号：US11919935B2

    公开(公告)日：2024-03-05

    申请号：US17523133

    申请日：2021-11-10

    申请人： Akston Biosciences Corporation

    发明人： Thomas M. Lancaster ,  Todd C. Zion

    IPC分类号： C12N5/16 ,  C07K14/62 ,  C07H21/04

    CPC分类号： C07K14/62 ,  C07H21/04 ,  C07K2319/30 ,  C07K2319/70 ,  C12N5/16

    摘要： The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.

    ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE
    6.
    发明申请
    ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE 有权

    公开(公告)号：US20210309709A1

    公开(公告)日：2021-10-07

    申请号：US17114395

    申请日：2020-12-07

    申请人： Akston Biosciences Corporation

    发明人： Thomas M. Lancaster ,  Todd C. Zion

    IPC分类号： C07K14/62 ,  A61P3/10 ,  A61K9/00 ,  C12N15/62

    摘要： The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of human origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, and does not exhibit immunogenicity requires a non-obvious combination of insulin polypeptide, peptide linkers, and Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.

    ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE
    9.
    发明申请
    ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE 有权

    公开(公告)号：US20220017590A1

    公开(公告)日：2022-01-20

    申请号：US17488852

    申请日：2021-09-29

    申请人： Akston Biosciences Corporation

    发明人： Thomas M. Lancaster ,  Todd C. Zion

    IPC分类号： C07K14/62 ,  A61P3/10 ,  A61K9/00 ,  C07K16/28 ,  C12N15/62 ,  A61K47/65 ,  C07K1/22 ,  C07H21/04

    摘要： The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine and feline diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine or feline origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.

    ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE
    10.
    发明申请
    ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE 有权

    公开(公告)号：US20220009990A1

    公开(公告)日：2022-01-13

    申请号：US17488685

    申请日：2021-09-29

    申请人： Akston Biosciences Corporation

    发明人： Thomas M. Lancaster ,  Todd C. Zion

    IPC分类号： C07K14/62 ,  A61P3/10 ,  A61K9/00 ,  C07K16/28 ,  C12N15/62 ,  A61K47/65 ,  C07K1/22 ,  C07H21/04

    摘要： The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine and feline diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine or feline origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.